Immunome (IMNM) vs Liquidia (LQDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunome (IMNM) has outperformed Liquidia (LQDA) over the past year, gaining 36.8% versus a gain of 12.9%. Over five years, LQDA leads with a +775.6% price change compared with +11.0% for IMNM. Liquidia is the larger company by market cap ($2.45 billion vs $2.31 billion), about 1.1 times the size.
Liquidia converts more of its revenue into profit, with a net margin of -43.5% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | LQDA |
|---|---|---|
| Share price | $19.55 | $27.38 |
| Market cap | $2.31B | $2.45B |
| 1-day change | +1.24% | -2.28% |
| YTD return | -8.99% | -20.61% |
| 1-year return | +36.81% | +12.91% |
| 5-year return | +11.02% | +775.63% |
| P/E ratio (TTM) | — | 19.70 |
| Forward P/E | — | 11.81 |
| EPS (TTM) | $-2.52 | $1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | $158.32M |
| Revenue growth (YoY) | -23.23% | +1031.18% |
| Net income (latest FY) | $-212.39M | $-68.92M |
| Operating margin | -3228.83% | -32.45% |
| Net margin | -3059.99% | -43.53% |
| 52-week high | $30.06 | $93.61 |
| 52-week low | $13.49 | $21.94 |
| Distance from 52-week high | -34.96% | -70.75% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +80.05% | +81.41% |
| Average volume | 1.20M | 2.47M |
| Shares outstanding | 118.00M | 89.51M |
| Employees | 247 | 216 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed LQDA by 23.9 percentage points over the past year.
- Liquidia is more profitable, keeping -43.5 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- Liquidia grew revenue faster in its latest fiscal year (+1031.18% vs -23.23%).
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Liquidia
LQDA stock →Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Health Care · Biotechnology: Pharmaceutical Preparations · 216 employees
IMNM vs LQDA FAQ
Which is bigger, Immunome or Liquidia?
Liquidia (LQDA) is larger, with a market capitalization of $2.45B compared with $2.31B for Immunome (IMNM).
Which stock has performed better over the past year, IMNM or LQDA?
IMNM returned +36.81% over the past 12 months, compared with +12.91% for LQDA (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Liquidia in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.